Narcolepsy Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035

Report Value Proposition – Why Does This Narcolepsy Market Report Matter?

This report covers the 7 major markets (the US, France, Germany, Italy, Spain, the UK, and Japan) and provides an Excel-based forecast model for the narcolepsy market through 2035. The narcolepsy therapeutics market totaled $4.6 billion in 2025 and is projected to grow at a 5.5% CAGR to $7.8 billion by 2035, mainly driven by the entry of orexin agonists from the late-stage pipeline, the introduction of new formulations, and increased treatment rates. The report combines disease management, epidemiology, pipeline assessment, unmet needs, and drug forecasts in one view.

What Will You Learn from This Report?

• How the narcolepsy therapeutics market is expected to grow from $4.6 billion in 2025 to $7.8 billion by 2035 at a 5.5% CAGR, and what is driving that growth
• Why the US has the largest narcolepsy market, accounting for approximately 97% of 7MM sales in 2025 and 2035, due to higher drug prices, large diagnosed prevalent cases, and the most product launches during the forecast period
• An overview of narcolepsy, including epidemiology, symptoms, diagnosis, and disease management
• Annualized market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2025 to 2035
• Strategic competitor assessment, market characterization, unmet needs, and clinical trial mapping, and their implications for the market
• Emerging trends and mechanisms of action in the pipeline, with the most promising late-stage candidates profiled
• The key industry drivers, restraints, and challenges, each independently researched for qualitative analysis of its implications

Scope

This report covers the 7 major markets (the US, France, Germany, Italy, Spain, the UK, and Japan) and provides an Excel-based forecast model for the narcolepsy market through 2035.

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM narcolepsy therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM narcolepsy therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Who Should Buy This Report?

This report is built for organizations competing in or entering the narcolepsy therapeutics market, including pharmaceutical and biotech companies, business development and licensing teams, commercial strategy teams, and investors assessing pipeline products and emerging players.

How Organizations Use This Narcolepsy Market Analysis

Organizations use this analysis to design in-licensing and out-licensing strategies through a review of pipeline products and technologies; develop business strategies by understanding the trends shaping the 7MM narcolepsy therapeutics market; formulate sales and marketing strategies by analyzing the competitive landscape and competitor performance; identify emerging players with potentially strong product portfolios and create counter-strategies; and organize sales and marketing efforts around the segments that offer the most opportunity for consolidations, investments, and strategic partnerships.

Key Highlights

The narcolepsy therapeutics market totaled $4.6 billion in 2025 across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan).

It is projected to grow rapidly at 5.5% compound annual growth rate (CAGR) to $7.8 billion by 2035, mainly driven by the entry of orexin agonists from the late-stage pipeline, the introduction of new formulations, and increased treatment rates.

The US has the largest narcolepsy market, accounting for approximately 97% of 7MM sales in 2025 and 2035, due to higher drug prices, the large diagnosed prevalent cases of narcolepsy, and the most product launches during the forecast period.

Reasons to Buy

• Benchmark Your Strategy Against Leaders/Competitors: Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of competitors, including key players such as Jazz Pharmaceuticals, Takeda, Alkermes, Harmony Biosciences, and Axsome Therapeutics.
• Identify Key Market Opportunities and Risks: Identify emerging players with potentially strong product portfolios and the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships, alongside the key drivers, restraints, and challenges.
• Make Better-Informed Strategic Decisions: Develop and design your in-licensing and out-licensing strategies by reviewing pipeline products and technologies and identifying the companies with the most robust pipeline.
• Understand Market Trends and Future Outlook: Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM narcolepsy therapeutics market through 2035.

Built on Trusted GlobalData Intelligence

This report draws on GlobalData’s epidemiology, pipeline, and clinical trial analysis, primary research, and an Excel-based forecast model, giving you a data-backed view of the 7MM narcolepsy therapeutics market through 2035.

Order Now and Strengthen Your Position in the Narcolepsy Market

Get ahead of the shift toward orexin agonists and new formulations. Order the full report today to assess the pipeline, benchmark your competitors, and plan your strategy for a market projected to reach $7.8 billion by 2035.